Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304,...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

CalculatedSwing Mar. 9 at 9:39 AM

$OCGN $OCGN loading up big time here at these levels! 🔥 CEO just laid out the roadmap: Full Phase 2 OCU410 data DROPPING THIS MONTH (building on that killer prelim 46% lesion reduction in GA/dry AMD – p=0.015, solid safety!). Phase 3 start for OCU410 in 2026, rolling BLA for OCU400 already on track for Q3 2026 after smashing Phase 3 enrollment completion. Multiple catalysts lined up: 3 potential BLAs in the next couple years, cash runway extended into late 2026, and analysts still holding Buy ratings with targets up to $8–$15. This dip is a gift – biotech beast mode incoming once data hits! Who’s with me? 🚀🧬💰 #OCGN #GeneTherapy #Biotech #OCU410 #OCU400$CRSP $NTLA $BEAM $RGNX

1 · Reply

3DBuilds Mar. 9 at 2:45 AM

$BEAM $CRBU $CRSP $EDIT $NTLA

0 · Reply

BioTechHealthX Mar. 8 at 4:33 PM

$BEAM $CORT $DYN $LEGN $OLMA Looking for the best biotechnology stocks to buy now? Analysts say these 10 biotech stocks could deliver more than 50% upside as breakthroughs in gene therapy, immuno-oncology, and RNA medicine reshape the healthcare industry. https://biotechhealthx.com/biotech-news/10-best-biotechnology-stocks-to-buy-now-with-more-than-50-upside-potential/

1 · Reply

jewell69 Mar. 6 at 7:39 PM

$BEAM day trade 3/6 03/06/2026 Sell Edit cost basis method BEAM BEAM THERAPEUTICS INC 50 $26.7234 $0.01 $1,336.16 More 03/06/2026 Buy BEAM BEAM THERAPEUTICS INC 50 $26.30 -$1,315.00 More Total $0.01 $21.16 bottom line profit we will be selling $ADBE and $COLL on a mkt on close basis (just 50 shares each; day trading with an eye dropper )

0 · Reply

jewell69 Mar. 6 at 5:43 PM

buying on the dip with an eye dropper 03/06/2026 Buy ADBE ADOBE INC 6 $278.88 -$1,673.28 More 03/06/2026 Buy COLL COLLEGIUM PHARMACEUTICAL 50 $36.74 -$1,837.00 More 03/06/2026 Buy BEAM BEAM THERAPEUTICS INC 50 $26.30 -$1,315.00 $ADBE $COLL $BEAM fwiw I didn't buy $CDNS at 297.xx new topic: 2 days ago Iran missle launches down 73% today 3/6/26 Iran missle launches down 90%

0 · Reply

Stocks86777 Mar. 6 at 4:52 PM

$BEAM shorts are cooked

0 · Reply

Stocks86777 Mar. 6 at 4:43 PM

$BEAM Going to 28 or even 29 #bullish

0 · Reply

Following_the_trend Mar. 6 at 3:37 PM

$BEAM In again this am mid 25's

0 · Reply

ScotchHat Mar. 6 at 5:31 AM

$HIGH.X Something is happening here...$ETH, $SOL, $ASM, $GODS, $BEAM, $SUPER

0 · Reply

Poker_Face Mar. 5 at 5:41 PM

$BEAM https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/585858/beam-therapeutics-beam-receives-a-buy-from-evercore-isi/

0 · Reply

Beam Therapeutics: Great Potential, But Patience Is Needed

Feb 24, 2026, 4:57 PM EST - 13 days ago

Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 2:07 PM EST - 13 days ago

What's Going On With Beam Therapeutics Stock?

Feb 24, 2026, 7:01 AM EST - 13 days ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Feb 24, 2026, 7:00 AM EST - 13 days ago

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Feb 23, 2026, 4:00 PM EST - 14 days ago

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

Jan 14, 2026, 3:35 AM EST - 7 weeks ago

Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:54 PM EST - 7 weeks ago

Beam Therapeutics: Pivoting From Platform To Execution Stage

Jan 11, 2026, 5:00 PM EST - 2 months ago

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Dec 18, 2025, 4:01 PM EST - 2 months ago

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 8:00 AM EST - 3 months ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Dec 4, 2025, 2:39 PM EST - 3 months ago

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal

Nov 12, 2025, 7:00 AM EST - 4 months ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 4 months ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 4 months ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Oct 22, 2025, 10:19 AM EDT - 4 months ago

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Sep 9, 2025, 9:54 AM EDT - 6 months ago

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 4:51 AM EDT - 6 months ago

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 3, 2025, 8:38 PM EDT - 6 months ago

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 20, 2025, 10:07 AM EDT - 9 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 9 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 9 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 10 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 10 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 10 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 10 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 1 year ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 1 year ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 1 year ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 1 year ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 1 year ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 1 year ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 1 year ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 1 year ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

CalculatedSwing Mar. 9 at 9:39 AM

1 · Reply

3DBuilds Mar. 9 at 2:45 AM

$BEAM $CRBU $CRSP $EDIT $NTLA

0 · Reply

BioTechHealthX Mar. 8 at 4:33 PM

1 · Reply

jewell69 Mar. 6 at 7:39 PM

0 · Reply

jewell69 Mar. 6 at 5:43 PM

0 · Reply

Stocks86777 Mar. 6 at 4:52 PM

$BEAM shorts are cooked

0 · Reply

Stocks86777 Mar. 6 at 4:43 PM

$BEAM Going to 28 or even 29 #bullish

0 · Reply

Following_the_trend Mar. 6 at 3:37 PM

$BEAM In again this am mid 25's

0 · Reply

ScotchHat Mar. 6 at 5:31 AM

$HIGH.X Something is happening here...$ETH, $SOL, $ASM, $GODS, $BEAM, $SUPER

0 · Reply

Poker_Face Mar. 5 at 5:41 PM

$BEAM https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/585858/beam-therapeutics-beam-receives-a-buy-from-evercore-isi/

0 · Reply

LongT Mar. 4 at 6:26 PM

$NTLA $CRSP $BEAM $VRTX NTLA stock March upgrades after FDA hold lifted: Jones Trading: Upgraded to Buy (from Hold) with a $29 price target (Mar 4). William Blair: Upgraded to Outperform (from Market Perform) (Mar 2). Leerink Partners: Maintained Outperform, raised target to $29 (Mar 3). H.C. Wainwright: Maintained Buy, raised target to $30 (Mar 3). Citizens: Raised target to $28 (Mar 3).

1 · Reply

Buraku Mar. 3 at 11:47 PM

$BEAM wtf with this stock

0 · Reply

jewell69 Mar. 3 at 7:16 PM

$BEAM 3/3 2:15 pm est trying to re-enter 50 at 26.80 low so far for today 26.70 recent trades 03/02/2026 Sell BEAM BEAM THERAPEUTICS INC 50 $28.1896 $0.01 $1,409.47 More 03/02/2026 Buy BEAM BEAM THERAPEUTICS INC 50 $27.00 -$1,350.00

0 · Reply

Quantumup Mar. 3 at 12:41 PM

H.C. Wainwright reiterated $BEAM Buy/$80, and said, On February 24, Beam reported 4Q25 and full-year 2025 results and reiterated a catalyst-rich 2026 across its liver-targeted genetic disease and hematology franchises (link to deck). $PFE H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2028812319598281177?s=20

0 · Reply

bpeeters Mar. 2 at 7:58 PM

$BEAM ugly dump there

0 · Reply

jewell69 Mar. 2 at 5:50 PM

$BEAM day trade 03/02/2026 Sell BEAM BEAM THERAPEUTICS INC 50 $28.1896 $0.01 $1,409.47 More 03/02/2026 Buy BEAM BEAM THERAPEUTICS INC 50 $27.00 -$1,350.00

1 · Reply

bpeeters Mar. 2 at 5:41 PM

$BEAM is this the weakest of the bunch? Seeing NTLA and PRME both green

0 · Reply

3DBuilds Mar. 2 at 3:42 PM

$CRSP $NTLA $BEAM $CRBU $EDIT

2 · Reply

WallStreetBuyDip Mar. 1 at 3:54 AM

$BEAM at $28 while $BNTX trading at $110. BEAM showing 26% below average volume, BNTX with 57% lower volume. Both in the Genomics sector - are investors waiting for a sector catalyst to drive volume back up?

0 · Reply

roblake29 Feb. 27 at 11:59 PM

$BEAM My latest analysis on Beam Therapeutics. Here is why I've given it a 'buy' rating: https://seekingalpha.com/article/4876259-beam-therapeutics-great-potential-but-patience-is-needed

0 · Reply

bpeeters Feb. 27 at 5:02 PM

$BEAM this one is gonna rocket next week! Book it!

0 · Reply

CarbonSpirit Feb. 27 at 6:11 AM

$BEAM XBI cratering provided perfect momentum, to pull this down, as 34.20 was getting close to margin call time for smaller shorts and big loss for MM’s and Smart money funds who’d have to cover the calls upward. Same story was seen on all the high shorted shares that had recently seen strong growth.

0 · Reply

Market Cap	2.70B
Revenue (ttm)	139.74M
Net Income (ttm)	-79.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-57.24%
Debt to Equity Ratio	0.00

Volume	1,241,575
Avg Vol	1,847,938
Day's Range	N/A - N/A
Shares Out	101.86M
Stochastic %K	20%
Beta	2.12
Analysts	Strong Sell
Price Target	$47.47